SRR12202400
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.460
- KRAS_SIGNALING_DN+0.420
- ANGIOGENESIS+0.400
- COAGULATION+0.380
- MYOGENESIS+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- HEDGEHOG_SIGNALING+0.260
- SPERMATOGENESIS+0.250
- APICAL_JUNCTION+0.240
- XENOBIOTIC_METABOLISM+0.110
Top 10 suppressed
- MYC_TARGETS_V1-0.670
- OXIDATIVE_PHOSPHORYLATION-0.570
- PROTEIN_SECRETION-0.570
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.540
- MYC_TARGETS_V2-0.530
- UNFOLDED_PROTEIN_RESPONSE-0.500
- MTORC1_SIGNALING-0.490
- DNA_REPAIR-0.470
- MITOTIC_SPINDLE-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202442 | — | — | 0.953 |
| 2 | SRR1316624 | GTEX | — | 0.941 |
| 3 | SRR1394713 | GTEX | — | 0.939 |
| 4 | SRR1340301 | GTEX | — | 0.938 |
| 5 | R415 | — | — | 0.936 |
| 6 | SRR1451964 | GTEX | — | 0.936 |
| 7 | SRR662091 | GTEX | — | 0.935 |
| 8 | BS_PQ7CQFYR | Ganglioglioma | — | 0.935 |
| 9 | TCGA-ZF-A9R9-01A-11R-A38B-07 | — | — | 0.934 |
| 10 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.931 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.460 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.420 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.030 | Inavolisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |